摘要
In 75%of women with polycystic ovary syndrome(PCOS),insulin action is impaired.In obesity,visceral adipose tissue becomes dysfunctional:Chronic inflammation is favored over storage,contributing to the development of metabolic complications.PCOS,metabolic syndrome(MetSy)and non-alcoholic fatty liver disease(NAFLD)apparently share common pathogenic factors;these include abdominal adiposity,excess body weight and insulin resistance.Alterations in the gut microbiome have been noted in women with PCOS compared to controls;these may lead to deterioration of the intestinal barrier,increased gut mucosal permeability and immune system activation,hyperinsulinemia and glucose intolerance,which hamper normal ovarian function and follicular development(all being hallmarks of PCOS).It has been proposed that PCOS may entail higher susceptibility to coronavirus disease 2019(COVID-19)via its associated comorbidities(NAFLD,obesity,MetSy and alterations in the gut microbiome).Studies have found an association between acute respiratory distress syndrome(seen in severe cases of COVID-19)and the intestinal microbiome.Furthermore,apparently,severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)can gain entry to the gastrointestinal tract via locally-expressed angiotensin converting enzyme type 2 receptors.Excess body weight is associated with more severe COVID-19 and increased mortality.Although robust links between SARS-CoV-2 infection and PCOS/NAFLD/gut microbiome/metabolic consequences are yet to be confirmed,it seems that strategies for adapting the intestinal microbiome could help reduce the severity of COVID-19 in women with PCOS with or without NAFLD,MetSy or obesity.
